| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000004089 |
| Receipt No. | R000004722 |
| Scientific Title | Quantitative capability and clinical usefulness of 11C-PiB-PET on known or suspected MCI patients |
| Date of disclosure of the study information | 2010/08/24 |
| Last modified on | 2020/01/24 (Ver. 5) |
| Basic information | ||
| Public title | Quantitative capability and clinical usefulness of 11C-PiB-PET on known or suspected MCI patients | |
| Acronym | Quantitative capability and clinical usefulness of PiB-PET on MCI (PiB-WB) | |
| Scientific Title | Quantitative capability and clinical usefulness of 11C-PiB-PET on known or suspected MCI patients | |
| Scientific Title:Acronym | Quantitative capability and clinical usefulness of PiB-PET on MCI (PiB-WB) | |
| Region |
|
|
| Condition | |||
| Condition | MCI(mild cognitive impairment) | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To measure the whole body distribution of PiB to evaluate the effect of activity outside the brain on quantitative capability in the early phase.
To evaluate the cortical deposition in the late phase to explore the clinical usefulness. |
| Basic objectives2 | Pharmacokinetics |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1.Whole-body distribustion of PiB in the early Phase
2.Cortical deposition of PiB in the late phase |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Diagnosis | ||
| Type of intervention |
|
||
| Interventions/Control_1 | PiB-PET | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with known or suspected MCI whom the referring physician considers that PiB-PET scan is clinically useful | |||
| Key exclusion criteria | 1) Cannot keep supine position for 100min
2) Large cerebral hemorrhage or infarction on MRI 3) Possibility of incomplete scan 4) Too much radiation exposure 5) Unsuitable for anyother reasons |
|||
| Target sample size | 10 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Institute of Biomedical Research and Innovation | ||||||
| Division name | Division of Molecular Imaging | ||||||
| Zip code | 650-0047 | ||||||
| Address | 2-2,Minatojima-Minamimachi,Chuo-ku,Kobe | ||||||
| TEL | 078-304-5212 | ||||||
| senda@fbri.org | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Institute of Biomedical Research and Innovation | ||||||
| Division name | Division of Molecular Imaging | ||||||
| Zip code | 650-0047 | ||||||
| Address | 2-2,Minatojima-Minamimachi,Chuo-ku,Kobe | ||||||
| TEL | 078-304-5212 | ||||||
| Homepage URL | |||||||
| senda@fbri.org | |||||||
| Sponsor | |
| Institute | Institute of Biomedical Research and Innovation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Foundation of Biomedical Research and Innovation |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | IBRI ethics committee |
| Address | 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047 Japa |
| Tel | 078-306-1700 |
| rinri@fbri.org | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 先端医療センター(兵庫県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Unpublished |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | Radiol Phys Technol 10, 464-474, 2017 | ||||||
| Number of participants that the trial has enrolled | 10 | ||||||
| Results | See article above |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | See article above |
||||||
| Participant flow | See article above |
||||||
| Adverse events | None |
||||||
| Outcome measures | See article above |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004722 |